Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, published by BMJ PUBLISHING GROUP, is a leading interdisciplinary journal focused on advancing research and clinical practice in the field of gynecological oncology. With an ISSN of 1048-891X and an E-ISSN of 1525-1438, the journal has established itself as a vital resource since its inception in 1991, covering cutting-edge advancements through 2024 and beyond. The journal holds esteemed rankings, including Q1 in Obstetrics and Gynecology and Q2 in Oncology, highlighting its influence and high citation impact within the medical community. Its Scopus rankings underscore its prominence, placing it among the top 13% of journals in Obstetrics and Gynecology and the top 27% in Oncology. Although it does not currently offer Open Access options, the journal provides a platform for researchers, clinicians, and students to share significant findings and developments that shape the future of gynecological cancer research and treatment. The INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER stands as a significant pillar in the ongoing effort to improve patient outcomes and foster innovation in this critical area of healthcare.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Eurasian Journal of Medicine and Oncology is a premier international journal established by KARE PUBL, dedicated to the exploration and advancement of knowledge within the fields of Internal Medicine and Oncology. Published in Turkey, this periodical offers a unique platform for researchers, healthcare professionals, and students to disseminate innovative research findings and clinical insights. With a commendable impact reflected in its 2023 Scopus rankings—ranking #49 in Internal Medicine and #143 in Oncology—this journal occupies a vital role in the academic and professional dialogue surrounding contemporary medical challenges. Operating under an Open Access framework, the journal facilitates broad dissemination of knowledge, ensuring that significant research is accessible to a global audience. The ongoing convergence of research and clinical application from 2019 to 2024 positions the Eurasian Journal of Medicine and Oncology as an essential resource for those committed to advancing the frontiers of medicine and oncology in an increasingly interconnected world.

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.